Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/AIxCrypto Holdings, Inc./ EFFECT

SEC Filing · EFFECT

AIxCrypto Holdings, Inc.

AIXCNASDAQEQUITYCurrent

SEC Filing

Filed Sep 14, 2026Accepted Sep 15, 2026, 12:15 AM EDTCIK 1460702Accession 9999999995-26-002961
View company →Permanent SEC source ↗
Share

Company context

We are an early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. Our business now consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS).

Current securities

AIXCNASDAQ · EQUITY · Current

Recent company filings

  1. 424B3 filingSep 14, 2026
  2. S-1/A filingSep 9, 2026
  3. DEF 14C filingSep 4, 2026
  4. S-1/A filingSep 4, 2026
  5. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory ArrangementsAug 26, 2026

Document unavailable

This filing is not currently available in the archive. Read it on SEC EDGAR ↗